Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + Fludarabine + Busulfan Conditioning for Elderly AML
NCT03530085Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03530085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530085.